Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2022 4
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Sublingual buprenorphine/naloxone treatment is not affected by OPRM1 A118G and BDNF Va66Met polymorphisms, but alters the plasma beta-endorphin and BDNF levels in individuals with opioid use disorder.
Kaya-Akyüzlü D, Özkan-Kotiloğlu S, Bal C, Avcıoğlu G, Yalçın-Şahiner Ş, Şahiner İV. Kaya-Akyüzlü D, et al. Among authors: ozkan kotiloglu s. Environ Toxicol Pharmacol. 2022 Oct;95:103979. doi: 10.1016/j.etap.2022.103979. Epub 2022 Sep 26. Environ Toxicol Pharmacol. 2022. PMID: 36174909
Effects of UGT2B7 rs7662029 and rs7439366 polymorphisms on sublingual buprenorphine metabolism in heroin addicts: An improved PCR-RFLP assay for the detection of rs7662029 polymorphism.
Kaya-Akyüzlü D, Özkan-Kotiloğlu S, Bal C, Yalçın-Şahiner Ş, Avcıoğlu G, Danışman M. Kaya-Akyüzlü D, et al. Among authors: ozkan kotiloglu s. Environ Toxicol Pharmacol. 2022 Aug;94:103902. doi: 10.1016/j.etap.2022.103902. Epub 2022 Jun 10. Environ Toxicol Pharmacol. 2022. PMID: 35697190
Association of PDYN 68-bp VNTR polymorphism with sublingual buprenorphine/naloxone treatment and with opioid or alcohol use disorder: Effect on craving, depression, anxiety and age onset of first use.
Kaya-Akyüzlü D, Özkan-Kotiloğlu S, Yalçın-Şahiner Ş, Ağtaş-Ertan E, Özgür-İlhan İ. Kaya-Akyüzlü D, et al. Among authors: ozkan kotiloglu s. Eur J Pharmacol. 2022 Apr 15;921:174862. doi: 10.1016/j.ejphar.2022.174862. Epub 2022 Mar 7. Eur J Pharmacol. 2022. PMID: 35271823